S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

$22.99
+1.33 (+6.14%)
(As of 02/22/2024 ET)
Today's Range
$21.67
$23.09
50-Day Range
$21.10
$32.88
52-Week Range
$17.86
$34.28
Volume
1.38 million shs
Average Volume
2.08 million shs
Market Capitalization
$2.38 billion
P/E Ratio
24.20
Dividend Yield
N/A
Price Target
$33.79

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
47.0% Upside
$33.79 Price Target
Short Interest
Bearish
21.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.47mentions of Corcept Therapeutics in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
50.00%
From $0.66 to $0.99 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

65th out of 934 stocks

Pharmaceutical Preparations Industry

23rd out of 423 stocks


CORT stock logo

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

CORT Stock News Headlines

Corcept Therapeutics: Key Catalysts Ahead
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up on Strong Earnings
Sneaky CEO Hides Monster AI Stock Under Secret Trade Name
The public isn't supposed to know about this monster AI stock under $5...It’s technology is quietly the engine that runs new powerful artificial intelligence models like ChatGPT. And Wall Street is getting hungry for more shares.
Q4 2023 Corcept Therapeutics Inc Earnings Call
Recap: Corcept Therapeutics Q4 Earnings
Earnings Preview: Corcept Therapeutics
Jim Simons Bolsters Position in Corcept Therapeutics Inc
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/22/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
299
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$33.79
High Stock Price Target
$47.50
Low Stock Price Target
$25.00
Potential Upside/Downside
+47.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$106.14 million
Pretax Margin
25.82%

Debt

Sales & Book Value

Annual Sales
$482.38 million
Cash Flow
$0.97 per share
Book Value
$4.89 per share

Miscellaneous

Free Float
83,021,000
Market Cap
$2.38 billion
Optionable
Optionable
Beta
0.46

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report














CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued twelve-month target prices for Corcept Therapeutics' stock. Their CORT share price targets range from $25.00 to $47.50. On average, they expect the company's share price to reach $33.79 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2024?

Corcept Therapeutics' stock was trading at $32.48 on January 1st, 2024. Since then, CORT shares have decreased by 29.2% and is now trading at $22.99.
View the best growth stocks for 2024 here
.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 19,320,000 shares, an increase of 23.3% from the January 15th total of 15,670,000 shares. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is presently 14.4 days. Currently, 22.0% of the company's stock are sold short.
View Corcept Therapeutics' Short Interest
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.03. The biotechnology company earned $135.41 million during the quarter, compared to analysts' expectations of $129.27 million. Corcept Therapeutics had a net margin of 21.86% and a trailing twelve-month return on equity of 21.98%. Corcept Therapeutics's revenue was up 31.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.14 earnings per share.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $513.9 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.25%), Ingalls & Snyder LLC (8.10%), Parallel Advisors LLC (3.66%), Novo Holdings A S (2.34%), Dimensional Fund Advisors LP (2.24%) and Boston Trust Walden Corp (1.79%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 2/23/2024 by MarketBeat.com Staff